An example is a clinical trial with ruxolitinib (NCT03153982), a JAK1/2 inhibitor that is currently being evaluated in operable HNSCC patients who are planned for definitive surgery. The gene discussed is JAK1; the disease is head and neck squamous cell carcinoma.